Roche Holding AG (RHHBY) Stock Price & Analysis
Roche Holding AG (RHHBY) — price $52.25 (-0.19%), as of the Oct 2, 2026 trading session; market cap $333B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Roche Holding AG · RHHBY · Healthcare · Drug Manufacturers - General
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors.
Price as of Oct 2, 2026
Key Statistics
No publishable V2 score is available for this stock yet.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $52.25 | |
| Change on the day | -0.19% | |
| 52-week range | $40.07 – $60.85 | |
| Market capitalisation | $333B | |
| Price / earnings (trailing) | 22.51 | |
| Shares traded on the day | 81.8K | |
| Beta (volatility vs the S&P 500) | 0.35 | |
| Dividends per share (last 12 months) | $1.55 | |
| Dividend yield (last 12 months) | 2.97% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
It could be a little bit lower, but we will see a little bit of a ramp-up of that effect in the second half.
Alan Hippe · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Roche Holding AG (RHHBY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 4, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the RHHBY film — every key number, told as a short cinematic story
~2 min · open the film
What is Roche Holding AG (RHHBY), and what does it report?
Short answer · as of
Roche sells therapies across oncology, neuroscience, immunology and other disease areas, while its diagnostics operation supplies laboratory tests, instruments and reagents.
Research dated 2026-09-12.
Roche sells therapies across oncology, neuroscience, immunology and other disease areas, while its diagnostics operation supplies laboratory tests, instruments and reagents. Calling it merely a drug manufacturer misses a material part of the business: demand also comes from laboratories and healthcare systems running tests to detect or monitor disease.
What do the latest results show for Roche Holding AG (RHHBY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $37.44B. Against analyst estimates the company has EPS beat 3 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $38.52B Jul 23, 2026
- Latest report · revenue estimate
- $38.14B Jul 23, 2026
- Latest report · revenue vs estimate
- Above estimate Jul 23, 2026
- Latest report · EPS vs estimate
- Above estimate Jul 23, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Jul 23, 2026 | $38.52B | $38.14B | $1.6600 | $1.5800 |
| Jan 29, 2026 | $39.70B | $38.96B | $1.3600 | $1.3500 |
| Jul 24, 2025 | $40.06B | $38.31B | $1.7400 | $1.6200 |
| Jan 30, 2025 | $33.83B | $33.84B | $1.1800 | $1.1700 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $37.44B | $8.47B | $1.31 (diluted) |
| Q4 FY2025 | $36.60B | $6.55B | $1.02 (diluted) |
| Q2 FY2025 | $19.22B | $4.47B | $0.70 (diluted) |
| Q4 FY2024 | $38.19B | $2.44B | $0.38 (diluted) |
What are the financial strengths and risks for Roche Holding AG (RHHBY)?
Short answer
The distress and quality screens read Altman Z 5.66 · Piotroski F 5. Trailing ratios: ROE 37.1% · ROA 12.6% · current ratio 1.23 · earnings yield 4.4% · free-cash-flow yield 5.4%.
What should you watch next at Roche Holding AG (RHHBY)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027. Current published price targets run low $63.00 · high $63.00 · consensus $63.00 · median $63.00 against a quoted price of $52.25 (as of Oct 2, 2026).
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
It could be a little bit lower, but we will see a little bit of a ramp-up of that effect in the second half.
Alan Hippe ·
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is Roche Holding AG scored?
Research dated 2026-09-12.
Roche combines medicine development with diagnostic testing under the same group. That makes its demand profile different from a pure pharmaceutical company or a stand-alone laboratory supplier: sales respond to clinical adoption of therapies as well as the use of tests, instruments and reagents across laboratory workflows.
| Company | Price | Market value | Score |
|---|---|---|---|
| $189.90 Mar 13, 2026 | $294B | — Model unavailable | |
| $38.27 Oct 2, 2026 | $63.0B | — Model unavailable | |
| $17.60 Oct 2, 2026 | $32.0B | — Model unavailable | |
| $144.30 Oct 2, 2026 | $356B | — 5-pillar · not comparable | |
| $141.00 Oct 2, 2026 | $268B | — 5-pillar · not comparable | |
| $262.82 Oct 2, 2026 | $464B | — 5-pillar · not comparable | |
| $403.04 Oct 2, 2026 | $218B | — 5-pillar · not comparable | |
| $256.03 Oct 2, 2026 | $617B | — 5-pillar · not comparable | |
| $144.74 Oct 2, 2026 | $179B | — 5-pillar · not comparable | |
| $27.80 Oct 2, 2026 | $158B | — 5-pillar · not comparable | |
| $61.15 Oct 2, 2026 | $125B | — 5-pillar · not comparable | |
| $1142.85 Oct 2, 2026 | $1.08T | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $63.00 – $63.00
- Consensus target
- $63.00
- Median target
- $63.00
Consensus record · Captured .
Measured against a quoted price of $52.25 (as of Oct 2, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 0.1% Period end Jun 30, 2026
- Previous quarter · ownership
- 0.1% Prior to period end Jun 30, 2026
- Reporting holders
- 71 Period end Jun 30, 2026
- Previous quarter · holders
- 68 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Aristotle Capital Management, LLC | 1,970,729 |
| Saratoga Research & Investment Management | 1,188,687 |
| Boston Common Asset Management, LLC | 300,155 |
| Old National Bancorp /In/ | 287,612 |
| S&Co INC | 230,310 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Roche Holding AG (RHHBY)?
- Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
- Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
- Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
- Roche's Enicepatide Shows Weight Loss, HbA1c Gains in Phase II Study
Roche Holding AG Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last 3 questions are answered from this page's own dated data, not from the research.
Why is Roche more than a pharmaceutical manufacturer?
Its pharmaceutical portfolio sits alongside a diagnostics business selling laboratory tests, instruments and reagents. Roche therefore participates in treatment decisions and in the testing used to identify and monitor disease.
What does Roche Diagnostics sell besides laboratory tests?
Roche Diagnostics also supplies instruments and reagents used by laboratories. Demand is therefore tied not only to test availability but also to testing activity across supported disease areas.
What is the RHHBY stock price today?
The last price recorded on this page for Roche Holding AG (RHHBY) is $52.25, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RHHBY price target?
The analyst consensus price target for Roche Holding AG (RHHBY) is $63.00 (range $63.00 to $63.00, median $63.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Does RHHBY pay a dividend?
Yes. Roche Holding AG (RHHBY) shows a trailing 12-month dividend yield of 2.97%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (53 figures)
The 53 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Alan Hippe (Jul 23, 2026): It could be a little bit lower, but we will see a little bit of a ramp-up of that effect in the second half. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. |
FMP — 43 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $52.25 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T09:24:51.734Z. | |
px.change | Change on the day | -0.19% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $333B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T09:24:50.721Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Feb 4, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.10 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 22.51 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 81.8K | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.35 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Thomas Schinecker | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 103,249 | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | Grenzacherstrasse 124, Basel, BS, 4070, CH | FMP | Financial Modeling Prep (FMP) company profile | |
fin.q_revenue | Revenue, Q2 FY2026 | $37.44B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-07-23.revenue_actual | Revenue · reported — report date 2026-07-23 | $38.52B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.revenue_estimated | Revenue · estimate — report date 2026-07-23 | $38.14B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_actual | EPS · reported — report date 2026-07-23 | $1.6600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-23.eps_estimated | EPS · estimate — report date 2026-07-23 | $1.5800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_actual | Revenue · reported — report date 2026-01-29 | $39.70B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.revenue_estimated | Revenue · estimate — report date 2026-01-29 | $38.96B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_actual | EPS · reported — report date 2026-01-29 | $1.3600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-01-29.eps_estimated | EPS · estimate — report date 2026-01-29 | $1.3500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.revenue_actual | Revenue · reported — report date 2025-07-24 | $40.06B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.revenue_estimated | Revenue · estimate — report date 2025-07-24 | $38.31B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.eps_actual | EPS · reported — report date 2025-07-24 | $1.7400 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-07-24.eps_estimated | EPS · estimate — report date 2025-07-24 | $1.6200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.revenue_actual | Revenue · reported — report date 2025-01-30 | $33.83B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.revenue_estimated | Revenue · estimate — report date 2025-01-30 | $33.84B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.eps_actual | EPS · reported — report date 2025-01-30 | $1.1800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-01-30.eps_estimated | EPS · estimate — report date 2025-01-30 | $1.1700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
earn.pt | Stored analyst price targets | low $63.00 · high $63.00 · consensus $63.00 · median $63.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_range | Analyst price target, low to high | $63.00 – $63.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $63.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $63.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.institutions.depth.ownership_pct | Institutional ownership | 0.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 0.1% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 71 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 68 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Aristotle Capital Management, LLC — shares in provider snapshot | 1,970,729 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Saratoga Research & Investment Management — shares in provider snapshot | 1,188,687 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Boston Common Asset Management, LLC — shares in provider snapshot | 300,155 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Old National Bancorp /In/ — shares in provider snapshot | 287,612 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | S&Co INC — shares in provider snapshot | 230,310 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $40.07 – $60.85 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-30 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 5.66 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 37.1% · ROA 12.6% · current ratio 1.23 · earnings yield 4.4% · free-cash-flow yield 5.4% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 4 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $1.55 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 2.97% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-07-23.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($38.52B) with the recorded estimate ($38.14B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-07-23.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($1.6600) with the recorded estimate ($1.5800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-07-23. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-07-23.revenue_actual,earn.history.depth.2026-07-23.revenue_estimated,earn.history.depth.2026-07-23.revenue_actual.comparison,earn.history.depth.2026-07-23.eps_actual.comparison,earn.history.depth.2026-07-23.eps_actual,earn.history.depth.2026-07-23.eps_estimated,earn.history.depth.2026-01-29.revenue_actual,earn.history.depth.2026-01-29.revenue_estimated,earn.history.depth.2026-01-29.eps_actual,earn.history.depth.2026-01-29.eps_estimated,earn.history.depth.2025-07-24.revenue_actual,earn.history.depth.2025-07-24.revenue_estimated,earn.history.depth.2025-07-24.eps_actual,earn.history.depth.2025-07-24.eps_estimated,earn.history.depth.2025-01-30.revenue_actual,earn.history.depth.2025-01-30.revenue_estimated,earn.history.depth.2025-01-30.eps_actual,earn.history.depth.2025-01-30.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Drug Manufacturers - General | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.
ETFs that hold RHHBY
Funds in our ETF coverage that list RHHBY among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| GMO International Quality ETF (QLTI) | 4.08% |